Combretastatin A4

Combretastatin A4 is a microtubule-targeting agent that binds β-tubulin with Kd of 0.4 μM.

Product Specifications

CAS Number

[117048-59-6]

Product Name Alternative

CRC 87-09

UNSPSC

12352005

Hazard Statement

H301+H311+H331, H318

Target

Microtubule/Tubulin

Type

Natural Products

Related Pathways

Cell Cycle/DNA Damage; Cytoskeleton

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/Combretastatin-A4.html

Concentration

10mM

Purity

99.94

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

OC1=CC(/C=C\C2=CC(OC)=C(OC)C(OC)=C2)=CC=C1OC

Molecular Formula

C18H20O5

Molecular Weight

316.35

Precautions

H301+H311+H331, H318

References & Citations

[1]Tochinai R, et al. Combretastatin A4 disodium phosphate-induced myocardial injury. J Toxicol Pathol. 2016 Jul;29 (3) :163-71.|[2]Signoretto E, et al. Stimulation of Eryptosis by Combretastatin A4 Phosphate Disodium (CA4P) . Cell Physiol Biochem. 2016;38 (3) :969-8|[3]Zhu J, et al. Co-Encapsulation of Combretastatin-A4 Phosphate and Doxorubicin in Polymersomes for Synergistic Therapy of Nasopharyngeal Epidermal Carcinoma. J Biomed Nanotechnol. 2015 Jun;11 (6) :997-1006.|[4]Yao N, et al. Combretastatin A4 phosphate treatment induces vasculogenic mimicry formation of W256 breast carcinoma tumor in vitro and in vivo. Tumour Biol. 2015 Nov;36 (11) :8499-510